



## PRESS RELEASE

### New Chairman of the Board of Directors of Rx&D

**Ottawa (November 17, 2004)** -*Canada's Research-Based Pharmaceutical Companies (Rx&D)* is pleased to announce the appointment of André Marcheterre, president of Merck Frosst Canada & Co. and of Merck Frosst Canada Ltd., as chairman of the Board of Directors.

André Marcheterre has a long and distinguished history in the pharmaceutical industry. He began with Merck Frosst in 1977, filling increasingly responsible positions in the areas of Marketing and Government Relations. In 1995, he was named vice-president of the Central Atlantic Marketing Group, part of the U.S. Human Health Division. A year later, in December 1996, he was appointed to his present position.

Mr. Marcheterre's community involvement is well known. Mr. Marcheterre is a member of the Board of Directors of Desjardins Sécurité Financière. He is also a board member of the Life Sciences Committee of Montréal International, and a governor of the Jeune chambre de commerce de Montréal.

Prior to his appointment, Mr. Marcheterre played a leading role in *Canada's Research-Based Pharmaceutical Companies (Rx&D)*. He served as a member of the Board of Directors and of the Executive Committee and chaired the Quebec Regional Committee for the past two years.

At Merck Frosst Canada & Co. and Merck Frosst Canada Ltd., Mr. Marcheterre directs a leading-edge pharmaceutical research company employing more than 1,900 persons, including 300 scientists.

*Canada's Research-Based Pharmaceutical Companies (Rx&D)* is an association of members dedicated to improving the health of all Canadians. As partner of the health care system, our discoveries help eliminate the need for medical procedures such as surgery, which have a significant impact on patient quality of life and health care budgets. Our community represents more than 24,000 men and women working for 54 member companies in Canada.

- 30 -

For information:

François Lessard  
Communications  
Rx&D  
613-236-0455